Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
Source abstract
Abstract
A major goal in cancer research is to develop carriers that can deliver drugs effectively and without side effects. Liposomal and particulate carriers with diameters of ∼100 nm have been widely used to improve the distribution and tumour accumulation of cancer drugs, but so far they have only been effective for treating highly permeable tumours. Here, we compare the accumulation and effectiveness of different sizes of long-circulating, drug-loaded polymeric micelles (with diameters of 30, 50, 70 and 100 nm) in both highly and poorly permeable tumours. All the polymer micelles penetrated highly permeable tumours in mice, but only the 30 nm micelles could penetrate poorly permeable pancreatic tumours to achieve an antitumour effect. We also showed that the penetration and efficacy of the larger micelles could be enhanced by using a transforming growth factor-β inhibitor to increase the permeability of the tumours.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Glioma Diagnosis and Treatment
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (36)
Show source-provided references
1. Duncan, R. The dawning era of polymer therapeutics. Nature Rev. Drug Discov. 2, 347–360 (2003).10.1038/nrd1088 ↗
2. Ferrari, M. Cancer nanotechnology: opportunities and challenges. Nature Rev. Cancer. 5, 161–171 (2005).10.1038/nrc1566 ↗
3. Torchilin, V. P. Recent advances with liposomes as pharmaceutical carriers. Nature Rev. Drug Discov. 4, 145–160 (2005).10.1038/nrd1632 ↗
4. Davis, M. E., Chen, Z. & Shin, D. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nature Rev. Drug Discov. 7, 771–782 (2008).10.1038/nrd2614 ↗
5. Kataoka, K., Harada, A. & Nagasaki, Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv. Drug Deliv. Rev. 47, 113–131 (2001).10.1016/S0169-409X(00)00124-1 ↗
6. Nishiyama, N. & Kataoka, K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Ther. 112, 630–648 (2006).10.1016/j.pharmthera.2006.05.006 ↗
7. Matsumura, Y. & Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumouritropic accumulation of proteins and the antitumour agent SMANCS. Cancer Res. 46, 6387–6392 (1986).
8. Nishiyama, N. et al. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumours in mice. Cancer Res. 63, 8977–8983 (2003).
9. Bae, Y. et al. Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjug. Chem. 16, 122–130 (2005).10.1021/bc0498166 ↗
10. Cabral, H., Nishiyama, N. & Kataoka, K. Optimization of (1,2-diamino-cyclohexane) platinum(II)-loaded polymeric micelles directed to improved tumour targeting and enhanced antitumour activity. J. Control. Release 121, 146–155 (2007).10.1016/j.jconrel.2007.05.024 ↗
11. Maruyama, K., Ishida, O., Takizawa, T. & Moribe, K. Possibility of active targeting to tumor tissue with liposome. Adv. Drug Deliv. Rev. 40, 89–102 (1999).10.1016/S0169-409X(99)00042-3 ↗
12. Lammers, T. et al. Image-guided and passively tumor-targeted polymeric nanomedicines for radiochemotherapy. Br. J. Cancer 99, 900–910 (2008).10.1038/sj.bjc.6604561 ↗
13. Matsumura, Y. & Kataoka, K. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci. 100, 572–579 (2009).10.1111/j.1349-7006.2009.01103.x ↗
14. Matsumura, Y. Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect. Adv. Drug Deliv. Rev. 63, 184–192 (2011).10.1016/j.addr.2010.05.008 ↗
15. Working, P. K. et al. Pharmacokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in stealth liposomes (DOXIL). J. Liposome Res. 4, 667–687 (1994).10.3109/08982109409037065 ↗
16. Northfelt, D. W. et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J. Clin. Oncol. 16, 2445–2451 (1998).10.1200/JCO.1998.16.7.2445 ↗
17. Gradishar, W. J. et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23, 7794–7803 (2005).10.1200/JCO.2005.04.937 ↗
18. Uster, P. S., Working, P. K. & Vaage, J. Pegylated liposomal doxorubicin (DOXIL(R), CAELYX(R)) distribution in tumour models observed with confocal laser scanning microscopy. Int. J. Pharm. 162, 77–86 (1998).10.1016/S0378-5173(97)00415-8 ↗
19. Unezaki, S. et al. Direct measurement of the extravasation of polyethyleneglycol-coated liposomes into solid tumor tissue by in vivo fluorescence microscopy. Int. J. Pharm. 144, 11–17 (1996).10.1016/S0378-5173(96)04674-1 ↗
20. Kano, M. R. et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumours by inhibition of TGF-β signaling. Proc. Natl Acad. Sci. USA 104, 3460–3465 (2007).10.1073/pnas.0611660104 ↗
21. Dreher, M. et al. Tumour vascular permeability, accumulation, and penetration of macromolecular drug carriers. J. Natl Cancer Inst. 98, 330–343 (2006).10.1093/jnci/djj070 ↗
22. Perrault, S. D., Walkey, C., Jennings, T., Fischer, H. C. & Chan, W. C. W. Mediating tumour targeting efficiency of nanoparticles through design. Nano Lett. 9, 1909–1915 (2009).10.1021/nl900031y ↗
23. Aliabadi, H. M. & Lavasanifar, A. Polymeric micelles for drug delivery. Exp. Opin. Drug. Deliv. 3, 139–162 (2006).10.1517/17425247.3.1.139 ↗
24. Matsumura, Y. et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br. J. Cancer 91, 1775–1781 (2004).10.1038/sj.bjc.6602204 ↗
25. Plummer, R. et al. A phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. Br. J. Cancer 104, 593–598 (2011).10.1038/bjc.2011.6 ↗
26. Cabral, H., Nishiyama, N., Okazaki, S., Kato, Y. & Kataoka, K. Preparation and biological properties of dichloro(1,2-diaminocyclohexane)platinum(II) (DACHPt)-loaded polymeric micelles. J. Control. Release 101, 223–232 (2005).10.1016/j.jconrel.2004.08.022 ↗
27. Nishiyama, N. & Kataoka, K. Preparation and characterization of size-controlled polymeric micelle containing cis-dichlorodiammineplatinum(II) in the core. J. Control. Release 74, 83–94 (2001).10.1016/S0168-3659(01)00314-5 ↗
28. Murakami, M. et al. Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting. Sci. Transl. Med. 3, 64ra2 (2011).10.1126/scitranslmed.3001385 ↗
29. Alexis, F., Pridgen, E., Molnar, L. K. & Farokhzad, O. C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 5, 505–515 (2008).10.1021/mp800051m ↗
30. Verma, A. et al. Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. Nature Mater. 7, 588–595 (2008).10.1038/nmat2202 ↗
31. Kano, M. R. et al. Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-β receptor inhibitor on extravasation of nanoparticles from neovasculature. Cancer Sci. 100, 173–180 (2009).10.1111/j.1349-7006.2008.01003.x ↗
32. Takahashi, Y. et al. Significance of vessel count, vascular endothelial growth factor, and its receptor (KDR) in intestinal-type gastric cancer. Clin. Cancer Res. 2, 1679–1684 (1996).
33. Sofuni, A. et al. Differential diagnosis of pancreatic tumours using ultrasound contrast imaging. J. Gastroenterol. 40, 518–525 (2005).10.1007/s00535-005-1578-z ↗
34. Matsumoto, Y. et al. Direct and instantaneous observation of intravenously injected substances using intravital confocal micro-videography. Biomed. Optics Exp. 1, 1209–1216 (2010).10.1364/BOE.1.001209 ↗
35. Choi, H. S. et al. Renal clearance of quantum dots. Nature Biotechnol. 25, 1165–1170 (2007).10.1038/nbt1340 ↗
36. Terada, Y. et al. Construction and commissioning of BL37XU at SPring-8. AIP Conf. Proc. 705, 376–379 (2004).10.1063/1.1757812 ↗